Terumo Acquires 5% of Fuji Pharma To Grow Drug/Device Combo Product Business
This article was originally published in PharmAsia News
TOKYO - Japanese device maker Terumo Corp. reached an agreement to purchase 5 percent of Fuji Pharma common shares for jointly developing a drug and device combination product business in Japan - the first such convergence undertaking in a country where the government in the past administered the pharmaceutical and medical device markets almost separately
You may also be interested in...
Japanese medical device maker Terumo announced Jan. 8 that the company plans a February launch of Premiage P400, a blood pressure monitor that is applied on the wrist. According to the company, the device will be targeted at females in their 50s who are most likely to develop lifestyle diseases such as hypertension. Priced at around ¥10,000, the product also comes in four colors, including pink and beige. (Click here for more - Japanese language
TOKYO - Terumo plans to expand its product line of cerebral aneurysm and other brain treatment devices in the U.S. and overseas markets with hopes of reaching ¥10 billion ($992 million) in cerebral aneurism device sales by March 2011, Terumo said Sept. 3
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).